论文部分内容阅读
美国批准了一种副作用的发生率明显低于全细胞百日咳菌苗的百日咳无细胞菌苗,它可用作DPT菌苗的第4和第5针加强接种的成分。美国公共卫生署主任Mason说,这种菌苗对大多数儿童接种有效。这种由美国食品与药物管理局批谁的百日咳无细胞菌苗,是具有百日咳抗原的无细胞滤液所组成。在进行研究以前,头3针的免疫接种仍用全细胞菌苗。还说,重要的是这种菌苗能预防严重的和致死性疾病,全细胞菌苗引起的手臂疼痛和发热的并发症,以及偶而引起的严重不良反应均大于
The United States has approved a B. pertussis cell-free bacterin that has a significantly lower incidence of side effects than the whole-cell pertussis vaccine and can be used as an adjunct to the fourth and fifth needles of DPT vaccine. Mason, director of the U.S. Department of Public Health, said the vaccine is effective for most children. This Pertussis-Free Bacterial vaccine approved by the U.S. Food and Drug Administration is a cell-free filtrate with pertussis antigens. Before conducting the study, the first 3 doses of the vaccine still use whole cell vaccine. It is also important to note that this bacterin can prevent severe and fatal diseases, complications of arm pain and fever caused by whole cell vaccines, and occasionally serious adverse reactions are greater than